Finding new ways to treat glioblastoma brain tumors
Integrated ligand and target discovery by chemical proteomics for glioblastoma treatment.
This project looks for new weaknesses in glioblastoma brain tumors to develop more effective treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11122221 on NIH RePORTER |
What this research studies
Glioblastoma is a very aggressive brain cancer where a gene called EGFR often drives tumor growth, but current EGFR medicines haven't worked well for patients. Our team has found that EGFR is often found on special DNA pieces called ecDNA, which helps tumors become resistant to treatment. We are using advanced chemistry techniques to discover new proteins that these resistant glioblastoma cells depend on to survive. The goal is to find new targets for medicines that can overcome the challenges of tumor diversity and drug resistance.
Who could benefit from this research
Good fit: This foundational work is for future patients with glioblastoma, especially those whose tumors have EGFR amplification.
Not a fit: Patients whose glioblastoma does not involve EGFR amplification may not directly benefit from treatments developed through this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to the development of entirely new and more effective drug treatments for patients with glioblastoma.
How similar studies have performed: This project builds on the team's recent discoveries about glioblastoma biology and integrates novel chemical approaches to find new drug targets.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Mischel, Paul S — Stanford University
- Study coordinator: Mischel, Paul S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.